Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Jun 14, 2014; 20(22): 6786-6808
Published online Jun 14, 2014. doi: 10.3748/wjg.v20.i22.6786
Published online Jun 14, 2014. doi: 10.3748/wjg.v20.i22.6786
Table 7 Systemic treatment of colon cancer
| Adjuvant therapy (stage III and stage II with high-risk features for systemic recurrence) |
| FOLFOX |
| CapeOx |
| If oxaliplatin is contraindicated or elderly patients |
| Capecitabine |
| 5-FU/Leucovorin |
| Metastatic disease (stage IV) |
| Resectable disease (lung, hepatic or peritoneal metastasis) |
| Consider surgery and/or locoregional treatment (radiofrequency, stereotactic radiotherapy) and 6 mo of perioperative chemotherapy (FOLFOX, CapeOx preferred) |
| Potentially resectable |
| FOLFOX |
| FOLFIRI |
| FOLFOXIRI |
| Cetuximab + FOLFIRI (only KRAS wild type) |
| Panitumumab + FOLFOX (only KRAS wild type) |
| Bevacizumab + FOLFOX |
| Unresectable (palliative) |
| FOLFOX |
| CapeOx |
| FOLFIRI |
| FOLFOX + Bevacizumab |
| CapeOx + Bevacizumab |
| FOLFOX + Panitumumab (only KRAS wild type) |
| FOLFIRI + Panitumumab (only KRAS wild type) |
| FOLFIRI + Cetuximab (only KRAS wild type) |
| FOLFIRI + Aflibercept |
| Capecitabine |
| 5-FU/Leucovorin |
| Cetuximab + Irinotecan (only KRAS wild type) |
| Cetuximab monotherapy (only KRAS wild type) |
| Panitumumab monotherapy (only KRAS wild type) |
| Regorafenib |
- Citation: Binefa G, Rodríguez-Moranta F, Teule &, Medina-Hayas M. Colorectal cancer: From prevention to personalized medicine. World J Gastroenterol 2014; 20(22): 6786-6808
- URL: https://www.wjgnet.com/1007-9327/full/v20/i22/6786.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i22.6786